昂利康(002940.SZ):擬以4000萬元參與投資嘉興元徠
格隆匯 12 月 15日丨昂利康(002940.SZ)公佈,公司於2020年12月14日召開第二屆董事會第二十次會議,會議審議通過了《關於參與投資嘉興元徠元啟創業投資合夥企業(有限合夥)的議案》,公司擬參與投資嘉興元徠元啟創業投資合夥企業(有限合夥)(“合夥企業”或“嘉興元徠”)。該合夥企業擬認繳出資總額為人民幣3億元(以最終實際認繳金額為準),公司擬以自有資金認繳出資人民幣4000萬元。
合夥企業的目的是通過直接或間接的股權投資、準股權投資或從事與股權投資相關的活動,實現良好的投資收益,為合夥人創造滿意的投資回報。合夥企業將主要投資初創期、成長期和Pre-IPO的醫療健康及核心科技行業優質企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.